Dr. David DeRemer appointed president-elect of the Hematology/Oncology Pharmacy Association

Published: April 9th, 2019

Category: Faculty, News, Pharmacotherapy and Translational Research

David DeRemer, Pharm.D., BCOP, FCCP, FHOPA, a clinical associate professor of pharmacotherapy and translational research, was appointed president-elect of the Hematology/Oncology Pharmacy Association, or HOPA, during the organization’s annual conference in Fort Worth, Texas.

David DeRemer, Pharm.D., BCOP, FCCP, FHOPA

David DeRemer, Pharm.D., BCOP, FCCP, FHOPA

As president-elect, DeRemer will be responsible for strategic planning, participate in developing the annual budget and assist with committee appointments, among many other responsibilities. He joined HOPA in 2006 and served on the Board of Directors from 2015-17. In spring 2020, DeRemer will take over as president of HOPA.

HOPA is a nonprofit professional organization formed in 2004 to help oncology and hematology pharmacy practitioners and their associates provide optimal cancer care. HOPA supports research, conducts educational conferences to advance knowledge, encourages professional development and advocates for health policy issues that improve patient care. Currently, HOPA has more than 2,800 members, which includes oncology practitioners, as well as pharmacy administrators, researchers, residents, interns and technicians specializing in hematology/oncology practice.

DeRemer joins Almut Winterstein, Ph.D., president-elect of the International Society for Pharmacoepidemiology, and Chris McCurdy, Ph.D., past-president of the American Association of Pharmaceutical Scientists, in actively serving in a presidential leadership role of a national pharmacy organization. “It is truly remarkable to have three faculty from the same pharmacy college leading these national/international organizations at the same time,” said Julie Johnson, dean and distinguished professor of the UF College of Pharmacy.

Tagged as: